Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind gantenerumab trial in early Alzheimer's disease (Japan)
jRCT2080224569Phase 2Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of gantenerumab in Alzheimer's disease (AD) (3 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Change in amyloid PET SUVr. Started Feb 2019; status: completed.
02
Drugs
gantenerumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2080224569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224569.